Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEQUOIA: Ampreloxetine in nOH
NCT03750552Phase 3Completed
- Sponsor
- Theravance Biopharma, Inc.
- Start
- Jan 2019
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial in Neurogenic Orthostatic Hypotension (nOH) comparing Ampreloxetine with Placebo (2 arms). Primary endpoint: Change From Baseline in Orthostatic Hypotension Symptom Assessment (OHSA) Question #1 Score at 4 weeks. Started Jan 2019; status: completed.
02
Drugs
ampreloxetine
03
Conditions
Neurogenic Orthostatic Hypotension (nOH)
Beyond the preview
Go deeper on NCT03750552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03750552.